The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
Open accessAbstract
Summary We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long-term hematopoietic stem cell (LTHSC) phenotype. CML LTHSC demonstrated reduced homing and retention in the bone marrow (BM), related to decreased CXCL12 expression in CML BM, resulting from increased G-CSF production by leukemia cells. Altered cytokine expression in CML BM was associated with selective impairment of normal LTHSC growth and a growth advantage to CML LTHSC. Imatinib (IM) treatment partially corrected abnormalities in cytokine levels and LTHSC growth. These results were validated using human CML samples and provide improved understanding of microenvironmental regulation of normal and leukemic LTHSC and their response to IM in CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
Kondo, M., Weissman, I. L., & Akashi, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80453-5 · Cited by 2,253
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4
Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., et al. (1999) · Science · doi:10.1126/science.283.5403.845 · Cited by 1,644
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 3×
“Our results contrast with observations made in BC CML and acute myeloid leukemia, where more mature LMPP or GMP progenitors may acquire self-renewal and leukemia-initiating capacity (Jamieson et al., 2004; Sarry et al., 2011).”
Cited by
A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia
Baryawno, N., Przybylski, D., Kowalczyk, M. S., Kfoury, Y., Severe, N., Gustafsson, K., Kokkaliaris, K. D., Mercier, F., Tabaka, M., Hofree, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.040 · Cited by 884
Adult haematopoietic stem cell niches
Crane, G. M., Jeffery, E., & Morrison, S. J. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.53 · Cited by 712
Schepers, K., Pietras, E. M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., Wagers, A. J., Hsiao, E. C., & Passegué, E. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.009 · Cited by 614
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
Ye, H., Adane, B., Khan, N., Sullivan, T., Minhajuddin, M., Gasparetto, M., Stevens, B., Pei, S., Balys, M., Ashton, J. M., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.06.001 · Cited by 543
Kumar, B., Garcia, M., Weng, L., Jung, X., Murakami, J. L., Hu, X., McDonald, T., Lin, A., Kumar, A. R., DiGiusto, D. L., et al. (2018) · Leukemia · doi:10.1038/leu.2017.259 · Cited by 441
Self-citationNormal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
Schepers, K., Campbell, T. B., & Passegué, E. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.014 · Cited by 421
Hanoun, M., Zhang, D., Mizoguchi, T., Pinho, S., Pierce, H., Kunisaki, Y., Lacombe, J., Armstrong, S. A., Dührsen, U., & Frenette, P. S. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.06.020 · Cited by 381
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Self-citationCarey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
Neural Regulation of Hematopoiesis, Inflammation, and Cancer
Hanoun, M., Maryanovich, M., Arnal-Estapé, A., & Frenette, P. S. (2015) · Neuron · doi:10.1016/j.neuron.2015.01.026 · Cited by 265
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment
Dong, L., Yu, W.-M., Zheng, H., Loh, M. L., Bunting, S. T., Pauly, M., Huang, G., Zhou, M., Broxmeyer, H. E., Scadden, D. T., et al. (2016) · Nature · doi:10.1038/nature20131 · Cited by 262
Passaro, D., Di Tullio, A., Abarrategi, A., Rouault-Pierre, K., Foster, K., Ariza-McNaughton, L., Montaner, B., Chakravarty, P., Bhaw, L., Diana, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.001 · Cited by 258
Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1236 · Cited by 212
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., et al. (2014) · Blood · doi:10.1182/blood-2013-10-536078 · Cited by 223
Self-citationLeukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy
Duan, C.-W., Shi, J., Chen, J., Wang, B., Yu, Y.-H., Qin, X., Zhou, X.-C., Cai, Y.-J., Li, Z.-Q., Zhang, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.015 · Cited by 198
Welner, R. S., Amabile, G., Bararia, D., Czibere, A., Yang, H., Zhang, H., Pontes, L. L. D. F., Ye, M., Levantini, E., Di Ruscio, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.004 · Cited by 129
Dong, F., Hao, S., Zhang, S., Zhu, C., Cheng, H., Yang, Z., Hamey, F. K., Wang, X., Gao, A., Wang, F., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0512-1 · Cited by 121
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Loscocco, F., Visani, G., Galimberti, S., Curti, A., & Isidori, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00939 · Cited by 120
Neural regulation of bone and bone marrow
Maryanovich, M., Takeishi, S., & Frenette, P. S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031344 · Cited by 114
“The finding that characteristics of BM stromal cells in the CML mouse model were not completely reverted by imatinib administration (Zhang et al. 2012) points out one critical issue about currently performed therapies.”
BackgroundTargeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
HDAC3 is essential for DNA replication in hematopoietic progenitor cells
Summers, A. R., Fischer, M. A., Stengel, K. R., Zhao, Y., Kaiser, J. F., Wells, C. E., Hunt, A., Bhaskara, S., Luzwick, J. W., Sampathi, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60806 · Cited by 87
Lai, D., Chen, M., Su, J., Liu, X., Rothe, K., Hu, K., Forrest, D. L., Eaves, C. J., Morin, G. B., & Jiang, X. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8735 · Cited by 47
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells
Shah, M., Kumar, H., Qiu, S., Li, H., Harris, M., He, J., Abraham, A., Crossman, D. K., Paterson, A., Welner, R. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157421 · Cited by 11
Self-citationEx Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells
Patel, S. B., Kuznetsova, V., Matkins, V. R., Franceski, A. M., Bassal, M. A., & Welner, R. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.001 · Cited by 7
Metadata
- Authors
- Zhang, B., Ho, Y. W., Huang, Q., Maeda, T., Lin, A., Lee, S.-U., Hair, A., Holyoake, T. L., Huettner, C., & Bhatia, R.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 21
- Issue
- 4
- Pages
- 577-592
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1992382947
- Cited by
- 348
- References
- 42
- FWCI
- 16.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.